

# Aerodynamic Factors Responsible for the Deaggregation of Carrier-Free Drug Powders to Form Micrometer and Submicrometer Aerosols

P. Worth Longest · Yoen-Ju Son · Landon Holbrook · Michael Hindle

Received: 12 October 2012 / Accepted: 1 February 2013 / Published online: 8 March 2013  
© Springer Science+Business Media New York 2013

## ABSTRACT

**Purpose** To employ *in vitro* experiments combined with computational fluid dynamics (CFD) analysis to determine which aerodynamic factors were most responsible for deaggregating carrier-free powders to form micrometer and submicrometer aerosols from a capsule-based platform.

**Methods** Eight airflow passages were evaluated for deaggregation of the aerosol including a standard constricted tube, impaction surface, 2D mesh, inward radial jets, and newly proposed 3D grids and rod arrays. CFD simulations were implemented to evaluate existing and new aerodynamic factors for deaggregation and *in vitro* experiments were used to evaluate performance of each inhaler.

**Results** For the carrier-free formulation considered, turbulence was determined to be the primary deaggregation mechanism. A strong quantitative correlation was established between the mass median diameter (MMD) and newly proposed non-dimensional specific dissipation (NDSD) factor, which accounts for turbulent energy, inverse of the turbulent length scale, and exposure time. A 3D rod array design with unidirectional elements maximized NDSD and produced the best deaggregation with  $MMD < 1 \mu\text{m}$ .

**Conclusions** The new NDSD parameter can be used to develop highly effective dry powder inhalers like the 3D rod array that can efficiently produce submicrometer aerosols for next-generation respiratory drug delivery applications.

**KEY WORDS** dry power inhaler (DPI) · excipient enhanced growth (EEG) · non-dimensional specific dissipation (NDSD) · respiratory drug delivery · submicrometer inhaler

## ABBREVIATIONS

2D	two-dimensional
3D	three-dimensional
AS	albuterol sulfate
CFD	computational fluid dynamics
DPI	dry powder inhaler
ED	emitted dose
EEG	excipient enhanced growth
FPF	fine particle fraction
HPLC	high-performance liquid chromatography
HPMC	hydroxypropyl methylcellulose
LES	large eddy simulation
LPM	liters per minute
LRN	low Reynolds number
MMAD	mass median aerodynamic diameters
MMD	mass median diameter
MN	mannitol
MP	mouthpiece
MT	mouth-throat
NDSD	non-dimensional specific dissipation
NGI	Next Generation Impactor
PDA	photo diode array
R <sup>2</sup>	coefficient of determination
RH	relative humidity
SD	standard deviation

P. W. Longest · L. Holbrook  
Department of Mechanical and Nuclear Engineering  
Virginia Commonwealth University, Richmond, Virginia, USA

P. W. Longest · Y.-J. Son · M. Hindle  
Department of Pharmaceutics, Virginia Commonwealth University  
Richmond, Virginia, USA

P. W. Longest (✉)  
Virginia Commonwealth University, 401 West Main Street  
P.O. Box 843015, Richmond, Virginia 23284-3015, USA  
e-mail: pwlargest@vcu.edu

TB tracheobronchial  
UV ultraviolet

## INTRODUCTION

Dry powder inhalers (DPIs) are currently a popular platform for respiratory drug delivery (1–3). Advantages compared with other inhalation devices include ease of use, coordination between patient inhalation and dose delivery, and stable formulations. However, performance of these devices is often poor in terms of high mouth-throat (MT) deposition, which results in increased side effects, wasted medication, increased inter-subject variability, and low lung delivery of the drug (4–6). A primary issue in developing effective DPIs, for both drug/carrier and drug only formulations, is achieving adequate deaggregation of the powder to form an aerosol with a high fine particle fraction (FPF) that can avoid MT deposition and reach the lungs for local action or systemic absorption. Current testing and development of DPIs typically focuses on producing high FPFs, defined as the drug mass contained in aerosolized particles with aerodynamic diameters less than approximately 5  $\mu\text{m}$ . Mass median aerodynamic diameters in the range of 2–5  $\mu\text{m}$  are also considered necessary for effective performance. Typical FPFs for conventional and state-of-the-art DPIs are in the range of 20–70% with lung depositions of approximately 5–30% (2, 3, 7). As an example, the Flovent Diskus® DPI (GlaxoSmithKline, Raleigh, NC), which is one of the most frequently prescribed inhalers, has a FPF of 20% based on emitted dose and approximately 70% MT deposition for a fluticasone propionate formulation with a lactose carrier during correct usage by adults (8).

Efforts to improve DPI performance have focused on modifications to both the device and powder formulation (3, 9–12). Device modifications are typically based on aerodynamic properties that first fluidize the powder and then deaggregate the aerosol into fine particles. Previous studies have reviewed both aerodynamic and formulation factors that can influence DPI aerosol performance (3, 9–13). Considering the device, correlations are needed between aerodynamic factors and aerosol formation that can be used to understand, evaluate, and improve performance. Using a combination of *in vitro* testing and computational fluid dynamics (CFD) or analytical predictions of aerodynamic factors, associations have previously been developed for the aerosolization and delivery performance of both spray inhalers (14) and DPIs (15–18). Considering DPIs, improved powder deaggregation and higher FPFs are typically associated with elevated device resistance, pressure drop, and power input (19, 20). However, factors most responsible for aerosol formation and deaggregation in DPIs are likely to change with different formulation types and for different devices.

DPI formulation types can be carrier-based (drug attached to larger excipient particles), carrier-free (or drug only), and agglomerates (composed of large aggregates of smaller primary particles). For carrier-based systems, deaggregation measured as a function of FPF was associated with turbulence (13), turbulent shear stress (11, 21, 22), and wall impactions of particles (18). Considering a carrier-free formulation of mannitol as a model drug and the Aerolizer® DPI, a capsule-based device, Coates *et al.* demonstrated direct associations between a measure of turbulence (the integral scale strain rate) as well as inlet flow with FPF (15, 16, 23). Optimization of the Aerolizer device based on the analysis of Coates *et al.* and modified mouthpiece geometries produced a FPF of 63% with deposition in a MT replica of approximately 30% (24). For agglomerate formulations, Wong *et al.* indicated no correlation between flow-based parameters and FPF (25); however, impaction in the device appeared to be a primary deagglomeration mechanism (17, 25, 26). Using agglomerate impaction on inclined surfaces with optimized angles, Adi *et al.* (27) achieved maximum FPF (% loaded dose) values of approximately 30%.

In general, it appears that the deaggregation of carrier-based and large agglomerate formulations is most influenced by turbulence and impaction (11–13, 17, 18, 21, 22, 25, 26). It is expected that impaction breaks apart large aggregates and knocks smaller drug particles off of larger carriers. Turbulence plays a role in both increasing wall impactions by particle dispersion and breaking apart smaller particle structures. However, carrier-based formulations often do not require wall impactions for deaggregation. For example, studies of Xu *et al.* (11, 21, 22) in particular demonstrate excellent associations between turbulent shear stress and powder deaggregation in standardized entrainment tubes for carrier-based systems with conventional sized powders. For carrier-free formulations, deaggregating is strongly associated with turbulence (15, 16, 23). All of these associations are very useful for understanding aerosol formation and optimizing device performance. However, the only existing quantitative correlations established between aerodynamic factors and DPI performance are for turbulent shear stress *vs.* FPF in standardized entrainment tubes (11, 21, 22) and air flow rate (*Q*) *vs.* capsule emptying in the Aerolizer DPI (23). Quantitative correlations may be very useful in the device optimization process and for determining which aerodynamic factors are most influential in aerosol formation. Furthermore, these previous studies of DPI performance have focused almost exclusively on FPFs defined as drug mass in particles with aerodynamic diameters of 5  $\mu\text{m}$  and below. Considering mass median aerodynamic diameters (MMADs) or mass median diameters (MMDs) of even smaller aerosols may be useful for developing next-generation DPIs and respiratory drug delivery strategies.

Generating approximately micrometer ( $\text{MMD} \approx 1 \mu\text{m}$ ) and submicrometer ( $\text{MMD} < 1 \mu\text{m}$ ) aerosols from DPIs may be beneficial in a number of new respiratory drug delivery approaches. For example, nanoparticle or submicrometer formulations of poorly soluble drugs have been shown to improve dissolution and uptake characteristics in the lungs or in test dissolution systems (28–30). For improved lung delivery, the excipient enhanced growth (EEG) concept begins with approximately micrometer or submicrometer aerosols ( $\text{MMD} \leq 1 \mu\text{m}$ ) to minimize deposition in the extrathoracic airways. Previous studies indicate that EEG delivery provides negligible MT deposition ( $\sim 1\%$ ), significant aerosol size increase within the airways due to the inclusion of hygroscopic excipients, full lung retention of the aerosol, and high delivery efficiency to the lower tracheobronchial and alveolar airways (31–34). A primary challenge in creating submicrometer aerosols from a DPI is overcoming inter-particle forces that are known to increase relative to aerodynamic aerosolization forces as primary particle size is reduced (9, 11). As a result, producing an effective submicrometer DPI requires a thorough understanding of aerosol deaggregation and the development of new formulations and devices that are more effective at creating high fractions of submicrometer aerosols (35, 36). However, very little is known about aerosol deaggregation down to the submicrometer scale with few previous studies considering FPFs less than approximately  $5 \mu\text{m}$ .

In a series of studies, Son *et al.* (35–37) demonstrated the combination of particle engineering and DPI device selection and modification to effectively produce micrometer and submicrometer EEG aerosols. The model optimized formulation consisted of albuterol sulfate (AS), mannitol (MN), L-leucine, and poloxamer 188 in a ratio of 30/48/20/2% w/w, respectively. Mannitol was included as a model hygroscopic excipient to form EEG combination particles that increase in size after inhalation (34). Leucine has been employed as a dispersion enhancing agent (30, 38). In the commercial Aerolizer DPI, the emitted  $\text{FPF}_{5 \mu\text{m}}$  and  $\text{FPF}_1 \mu\text{m}$  were greater than 80% and 28%, respectively. The submicrometer combination particles had negligible ( $<5\%$ ) deposition in a MT model (37). By modifying a commercial DPI with a 3D rod array design, the emitted  $\text{FPF}_1 \mu\text{m}$  was increased to 38.8% ( $\text{FPF}_{5 \mu\text{m}} > 97\%$ ) and a submicrometer aerosol was formed with  $\text{MMD} < 1 \mu\text{m}$  (35). However, mechanisms responsible for particle deaggregation of the carrier-free formulation implemented and tested by Son *et al.* (35) to form submicrometer aerosols remains unclear. A better understanding of the aerodynamic factors that create micrometer and submicrometer aerosols will allow further optimization of DPI devices and improved FPFs at lower pressure drops.

The objective of this study was to employ *in vitro* experiments combined with CFD analysis to determine which

aerodynamic factors were most responsible for deaggregating carrier-free powders to form micrometer and submicrometer aerosols from a capsule-based platform. The previously developed carrier-free formulation of Son *et al.* (37) for an EEG aerosol was implemented that consists of submicrometer primarily particles. A capsule-based platform was selected as a uniform mechanism to initially fluidize the powder and a single capsule chamber was considered. Performances of different airflow pathways downstream of the capsule chamber were then evaluated in terms of aerosol deaggregation. The airflow pathways consisted of standard inhaler configurations for powder deaggregation such as a constriction tube, impaction surface, mesh, and inward jets, as well as newly proposed 3D grids and unidirectional rod arrays. CFD simulations were implemented to evaluate previously reported aerodynamic factors associated with deaggregation along with newly proposed parameters. *In vitro* experiments were conducted to evaluate the performance of each inhaler system in terms of FPFs ( $< 5 \mu\text{m}$  and  $< 1 \mu\text{m}$ ) as well as MMD. A single parameter was then sought that can best predict DPI performance across a range of inhalers at multiple flow rates with a carrier-free formulation for the production of micrometer and submicrometer aerosols. The best performing inhaler was then identified for future use in submicrometer aerosol delivery with the EEG approach.

## MATERIALS AND METHODS

### Inhalers and Flow Conditions

Multiple DPI designs were considered to evaluate different aerodynamic factors potentially affecting aerosol deaggregation for a carrier-free formulation of EEG combination particles delivering AS as the drug. The model EEG formulation was previously established by Son *et al.* (37) and was formed using a spray drying process. The spray dried powder was loaded into capsules in quantities of 2 mg and the capsules were pierced with a needle prior to aerosolization producing 2 holes 0.5 mm in diameter. For initial fluidization of the aerosol, the capsules for all inhaler designs were placed in the capsule chamber of the HandiHaler® (Boehringer Ingelheim Inc., Ridgefield, CT) device. Different airflow passages downstream of the capsule chamber were then considered to form different inhaler designs and evaluate the potential for effective deaggregation of the particles into micrometer and submicrometer aerosols. By selecting a single capsule chamber design and different downstream flow passages, this study focuses on how factors in the flow passage can deaggregate the aerosol after initial fluidization.


Aerosol deaggregating airflow passages were designed to focus on both turbulence and impaction as potential

breakup mechanisms. The airflow passages are illustrated in Fig. 1 and summarized in Table 1. The most basic design consisted of a constricted tube to increase turbulence (Inhaler 1), which represents the flow passage of the commercial HandiHaler device. To increase both particle-wall impactions and flow turbulence, Inhalers 2 and 3 incorporate a baffle style impaction surface (Inhaler 2), as exists in some air jet nebulizers, and a 2D mesh (Inhaler 3), which is very common for increasing powder deaggregation. Inhaler 4 implements inward radial jets to generate elevated turbulence,

consistent with the study of Voss and Finlay (13). It is currently not clear which existing turbulence generation mechanism is most efficient at deaggregating a powder for similar input flow rates or similar pressure drops.

A goal of an effective DPI is to maximize powder deaggregation while minimizing pressure drop. Therefore, airflow passages are sought that can maximize turbulence levels and particle exposure times to turbulence for a consistent or lower drop in pressure across the inhaler. Inhalers 5 and 6 seek to maximize the exposure of particles to

**Fig. 1** Flow passages of the inhalers implementing different designs for aerosol deaggregation. The inhaler numbers (Table 1) and descriptions are: (a) Inhaler 1 - constricted tube, (b) Inhaler 2 - internal impaction surface, (c) Inhaler 3 - 2D mesh of 0.5 mm wires, (d) Inhaler 4 - inward facing 0.5 mm jets, (e) Inhaler 5 - 3D grid of 0.5 mm rods, (f) Inhaler 6 - 3D array of 0.5 mm rods.



**Table 1** Inhalers Considered and Key Dimensions

Num.	Name	Deagglomeration mechanism	Critical dimensions of flow passages	Flow rates (LPM)
1	Constricted tube (commercial HandiHaler design)	Increases turbulence and/or wall impactions	Inlet diameter: <sup>a</sup> 10 mm Minimum diameter: 5.2 mm MP outlet: 19×7 mm	45
2	Impaction surface	Baffle surface located in center of constriction to increase impactions and promote turbulence	Minimum flow passage distance: 2 mm Baffle diameter: 3 mm MP outlet: 19×7 mm	45
3	2D grid	Increases turbulence and impaction using a 2D grid structure	Midsection containing mesh: 5.7×8.6 mm Mesh diameter: 0.5 mm MP outlet: 19×14 mm	45
4	Inward jets	Inward radial jets centralize the aerosol and create an area of high turbulence	Number of inward jets: 8 Diameter of jets: 0.5 mm Minimum diameter of flow passage: 5.7 mm MP outlet: 19×7 mm	60 and 75
5	3D grid	3D grid structure to amplify and extend the turbulent region	Midsection containing mesh: 5.7×8.6 mm Rod diameter: 0.5 mm MP outlet: 19×14 mm	45
6	3D array	Array of unidirectional rods to maximize turbulence over a larger area	Midsection containing rod array: 5.7×5.7 mm Rod diameter: 0.5 mm MP outlet: 19×7 mm	45 and 60
7	Expanded 3D array	Array of unidirectional rods with a larger cross-section in the turbulence generation region	Midsection containing rod array: 5.7×8.6 mm Rod diameter: 0.5 mm MP outlet: 19×14 mm	45
8	3D array with smaller rods	Array of unidirectional rods to maximize turbulence with reduced rod size to decrease pressure drop	Midsection containing rod array: 5.7×5.7 mm Rod diameter: 0.375 mm MP outlet: 19×7 mm	45

<sup>a</sup> The inlet configuration of a 10 mm circle is the same for all inhalers

turbulence by expanding the turbulence generation space using a 3D grid and array, respectively. The 3D grid consists of rows of 0.5 mm rods with each successive row rotated by 90°. For the 3D grid considered in this study, the rods are separated by a gap distance of 0.5 mm on each row and the rows are separated by gap distances of 0.75 mm in the direction of flow. The 3D array is characterized by rows of 0.5 mm unidirectional rods with gap distances identical to the 3D grid and staggered such that increased velocity between 2 rods impacts on the center of the rod in next row. Using these designs, it is expected that flow constriction in terms of reduced cross-sectional area and pressure drop are minimized compared with a 2D design, while turbulence generation and aerosol exposure time to elevated turbulence are maximized. To better understand aerodynamic factors within the rod array, the cross-sectional area of the array is increased with Inhaler 7 and smaller 0.375 mm rods are used in Inhaler 8. Key dimensions of all inhalers considered are reported in Table 1.

Flow rates through the eight devices were selected to be within the range of normal DPI usage for adults. As a baseline, a flow rate of 45 LPM was established for a

4 kPa total pressure drop through Inhaler 1. For consistency, all inhalers (except Inhaler 4) were tested at this flow rate and found to produce total pressure drops in the range of 4 kPa and well below the adult maximum of 7.8 kPa (39). For the low resistance Inhaler 4 device, a flow rate of 75 LPM was determined to produce 15 LPM total flow through the 8 inward jets with 60 LPM through the device and an approximate total device pressure drop of 4 kPa. Other flow rates were also tested in some devices to better understand the aerodynamic factors involved with deaggregation, such as 60 LPM in Inhaler 6. Calculated pressure drop through the airflow passages is reported in the Results section as an aerodynamic factor potentially correlating to FPF and was established to be in the range of 0.7 to 2 kPa. The Results section also includes a CFD comparison of all flow passages evaluated at a consistent pressure drop of 2 kPa.

### In Vitro Experiments

The airflow passages characterizing each of the eight tested inhalers were constructed using a rapid prototyping process.

An in-house Viper SLA machine (3D Systems, Valencia, CA) was used to build the geometries out of clear plastic resin (Accura 60; 3D Systems) using a build layer thickness of 0.10 mm and a laser spot diameter of 0.25 mm. Each airflow passage was connected to the capsule dispersion unit of the HandiHaler, and a wire mesh consistent with the commercial device prevented ingress of the capsule into the flow passage. Using this standard capsule dispersion unit (or chamber) at a constant set of flow rates allowed a consistent aerosol to be initially fluidized in each experiment. Subsequent deaggregation was then assessed as an effect of aerodynamic factors present in the different downstream airflow passages.

The process for obtaining the spray dried EEG powder was described by Son *et al.* (37) and consisted of conditions and formulation variables from Experiment 6 of that study. Briefly, the spray dried combination particles contained AS, MN, L-leucine, and poloxamer 188 in a ratio of 30/48/20/2% w/w, respectively. They were produced by spray drying (Buchi Nano spray dryer B-90) at an inlet temperature of 70°C from a water:ethanol 80:20%v/v solution containing 0.5% solids. Scanning electron microscopy showed that the spray dried particles were submicrometer sized with geometric diameters between 0.2–1.0  $\mu\text{m}$  (37). In the current study, a Next Generation Impactor (NGI; MSP Co., Shoreview, MN) was used to determine aerodynamic particle size characteristics of the drug in the combination particle formulations. A sample of each powder formulation (2 mg) was filled into size 3 HPMC capsules and placed into the HandiHaler capsule dispersion unit prior to testing. Each of the engineered airflow passages was connected to the capsule dispersion unit to form Inhalers 1–8. The DPIs were fired into a NGI through a pre-separator operating at an airflow rate of 45–75 LPM. The inhalation time was varied to draw 4 L of air through each inhaler at ambient conditions (25°C/45–55% RH). In order to assess the particle size distribution of the total dose of formulation, the USP induction port was omitted. For each of the impactor experiments, the impactor collection stages and pre-separator were coated with Molykore®316 silicone spray to minimize particle re-entrainment and bounce. Albuterol sulfate remaining in the DPIs (including the capsule), deposited on the pre-separator, and on each of the impactor collection stages was determined by washing each item with 10 mL of deionized water to extract the drug for quantitative analysis. Collected samples were analyzed using a validated HPLC method.

Drug emitted dose (ED) exiting the DPI was determined by subtracting the amount of AS remaining in the DPI from the initial mass of AS loaded. The initial mass loaded in the DPI was calculated from weight of combination formulation and the measured % AS content for each formulation. The drug fine particle fraction ( $\text{FPF}_{5 \mu\text{m}/\text{ED}}$ ) and submicrometer

particle fraction ( $\text{FPF}_{1 \mu\text{m}/\text{ED}}$ ), defined as the total emitted dose of AS with aerodynamic diameters smaller than 5  $\mu\text{m}$  and 1  $\mu\text{m}$ , respectively, were calculated *via* interpolation from the cumulative mass *versus* the cutoff diameter of the respective stages of the NGI, corrected for inlet flow rate. Each measurement was repeated three times. The MMAD was determined at the 50th percentile on the % cumulative undersize (probability scale) *versus* logarithmic aerodynamic diameter plot and converted to MMD values based on a measured skeletal density of 1.325 g/cm<sup>3</sup> for the combination particles.

The HPLC method for AS quantification employed a Waters 2690 separations module with a 2996 PDA detector (Waters Co., Milford, MA). Chromatography was performed using a Restek Allure PFP 15  $\times$  3.2 mm column (Bellefonte, PA). The mobile phase, consisting of methanol and ammonium formate buffer (20 mM, pH3.4) in a ratio of 70:30, respectively, was eluted at a flow rate of 0.75 mL/min and the UV detector was set to a wavelength 276 nm. The column temperature was maintained at 25°C, and the volume of each sample injected was 50  $\mu\text{L}$ .

## CFD Simulations

Computational fluid dynamics simulations were conducted for the eight inhaler flow passages and multiple flow rates described in Table I. Blunt inlet profiles were assumed to enter the flow passages with 1% turbulence intensity and a turbulence length scale equal to the mesh opening. Isothermal and steady state solutions were sought where possible. However, transient simulations were required to resolve flow oscillations occurring in some of the inhalers. Transient simulations were conducted with a time step of 0.001 s and at least 0.5 s of flow was resolved to ensure that startup effects were not present in the solution. Incompressible constant-property flow was also assumed in all cases. The inlet Reynolds number for the flow rates considered (Table I) ranged from 6,010 to 10,000, indicating the occurrence of turbulent flow, which was amplified in the presence of constrictions, internal bodies, and meshes.

The flow fields in each inhaler were solved using Fluent 12 (Ansys Inc., Canonsburg, PA) with a steady or transient solution and the low Reynolds number (LRN)  $k\text{-}\omega$  two-equation turbulence model. This turbulence model was selected based on its accuracy combined with high efficiency compared with more complex methods, such as large eddy simulation (LES). The LRN  $k\text{-}\omega$  model was previously demonstrated to accurately predict pressure drop, velocity profiles, and shear stress for transitional and turbulent flows (40, 41). The conservation of mass and momentum equations used with the LRN  $k\text{-}\omega$  model are available from Wilcox (41) and were previously reported by Longest and Xi (42). Similarly, the equations governing turbulent kinetic energy

( $k$ ) and specific dissipation rate ( $\omega$ ) were also reported by Longest and Xi (42). Considering aerosol transport, the LRN  $k$ - $\omega$  model was previously demonstrated to accurately predict particle transport and deposition for both monodisperse and polydisperse distributions in airway models on a regional and highly localized basis (43–46).

Particle trajectories were considered in each of the eight inhalers to evaluate impaction and as a method to sample the time course of aerosol exposure to turbulence. As a characteristic size of the spray dried formulation, an aerosol of monodisperse 1  $\mu\text{m}$  particles was considered. To accurately predict individual particle trajectories and record the time history of turbulence exposure on the discrete phase, a Lagrangian particle tracking algorithm was employed. The Lagrangian transport equations can be expressed

$$\frac{dv_i}{dt} = \frac{f}{\tau_p} (u_i - v_i) + g_i(1 - \alpha) + f_{i,Brownian} \text{ and } \frac{dx_i}{dt} = v_i(t) \quad (1)$$

Here  $v_i$  and  $u_i$  are the components of the particle and local fluid velocity,  $g_i$  denotes gravity, and  $\alpha$  is the ratio of mixture to particle density  $\rho/\rho_p$ . The characteristic time required for a particle to respond to changes in fluid motion, or the particle relaxation time, is expressed as  $\tau_p = C_c \rho_p d_p^2 / 18\mu$ , where  $C_c$  is the Cunningham correction factor for submicrometer aerosols based on the expression of Allen and Raabe (47),  $d_p$  is the particle diameter, and  $\mu$  is the absolute viscosity. The pressure gradient or acceleration term for aerosols was neglected due to small values of the density ratio (48). The drag factor  $f$ , which represents the ratio of the drag coefficient to Stokes drag, was based on the expression of Morsi and Alexander (49). The effect of Brownian motion on the trajectories of submicrometer particles was included as a separate force per unit mass term at each time-step (50). To model the effects of turbulent fluctuations on droplet trajectories, a random walk method was employed (51–53). A near-wall anisotropic correction to turbulent particle dispersion was also included (54, 55).

Computational grids of the airflow passages were constructed based on previously established best practices. Hexahedral elements were used wherever possible, based on the findings of previous studies (56, 57). Tetrahedral and wedge elements were required to resolve flow around the inlet jets and rod elements of the 2D mesh, 3D grid, and 3D arrays. For the hexahedral mesh, near wall mesh size was typically smaller than 0.075 mm. For the tetrahedral grids in the vicinity of the rods, near-wall mesh size was set at a constant 0.03 mm. The resulting 8 meshes had cell numbers ranging from 225,000 to 1,100,000. Grid convergence of these meshes was established by comparing with meshes containing at least 30% more cells in each case. These comparisons indicated that there were minimal differences

(< 5% relative error) in the maximum velocity and particle deposition values. As a result, the coarser meshes were considered sufficient and used in all subsequent simulations.

The CFD package Fluent 12 was used to solve the flow field and particle trajectory equations in each of the inhalers. User-supplied Fortran and C programs were used for the calculation of initial flow and particle profiles, near-wall anisotropic turbulence approximations, near-wall particle interpolation, and Brownian motion (50). All transport equations were discretized to be at least second order accurate in space. For the convective terms, a second order upwind scheme was used to interpolate values from cell centers to nodes. The diffusion terms were discretized using central differences. The particle trajectory solution was calculated using 4th-order Runge Kutta with an error control routine (48). Both wall impactions and discrete sampling of the turbulence field were conducted using 6,000 representative monodisperse 1  $\mu\text{m}$  particles with a density of 1.325 g/cm<sup>3</sup>. Simulating additional particles had a negligible effect on impaction results in terms of deposition fraction. Effects of particle number on turbulence sampling are described in the Discussion section.

## Deaggregation Factors

Possible deaggregation factors were categorized as flow-based, turbulence-based, and particle-based. Some overlap among the factors in each category is apparent. Equations, justifications, and previous sample references for each factor are provided in Table II. Additional descriptions of some factors are also discussed below along with a description of volume-averaging within the inhalers.

Considering flow-based parameters, the pressure drop reported in this study is calculated over the airflow passage-ways (Fig. 1). This approach for reporting  $\Delta P$  was implemented to focus on the pressure drop associated with deaggregation in the flow passage. However, it is understood that additional pressure is required to actuate the capsule dispersion portion of the device. The shear stress ( $\tau_s$ ) definition is based on the previous study of Xu *et al.* (11) and is apparently an approximation of the turbulent shear stress (which dominates laminar shear stress) in the flow field. To approximate this equation (Table II) with the CFD model, a volume-average of the eddy dissipation rate ( $\epsilon$ ) is calculated within the airflow passage, as described below.

Considering turbulent quantities, Table II describes local values of turbulent kinetic energy ( $k$ ), turbulence intensity (TI), and specific dissipation rate ( $\omega$ ) that exist throughout the 3D flow field. For example, the local TI represents the turbulent kinetic energy at a point that acts to break apart aggregates normalized by the time-averaged velocity (Table II). This normalization for TI is justified because

**Table II** Factors Expected to Influence Dispersion of the Aerosol

Factor name and symbol	Equation	Units	Justification	Reference
<b>Flow-based</b>				
Flow rate ( $Q$ )	$Q = \bar{V}A$	$\text{m}^3/\text{s}$	Flow rate increases turbulence, capsule motion, and impaction velocity of particles.	(23)
Pressure difference ( $\Delta P$ )	$\Delta P = P_{\text{outlet}} - P_{\text{inlet}}$	Pa (or $\text{N/m}^2$ )	Proportional to energy applied to the inhaler and powder during inhalation	(19)
Power	$\text{Power} = \Delta P \cdot Q$	Watts (W)	Rate of energy applied to the inhaler and powder during inhalation	(20)
Shear stress ( $\tau_s$ )	$\tau_s = \mu \left( \frac{\dot{\epsilon}}{\dot{\gamma}} \right)^{1/2}$	$\text{N/m}^2$	Shear stress in the flow field is capable of applying different forces on an aggregate to break it apart. Turbulent shear stress definition based on Xu et al. (11). Variables are absolute viscosity ( $\mu$ ), kinematic viscosity ( $\nu$ ), and eddy dissipation rate ( $\dot{\epsilon}$ ).	(11)
<b>Turbulence-based</b>				
Turbulent kinetic energy ( $k$ )	$k = \frac{1}{2} \left( \overline{u'^2} + \overline{v'^2} + \overline{w'^2} \right)$	$\text{m}^2/\text{s}^2$	Turbulent fluctuations are capable of breaking apart aggregates through shear and acceleration. Over-bars in $k$ equation represent time averaging. Primes indicate fluctuating turbulent properties	(41)
Turbulent intensity (TI)	$TI = \sqrt{\frac{2}{3}} \frac{k}{U^2} * 100$	Non-dimensional (%)	Represents the ratio of fluctuating velocity ( $k$ ) to time-averaged mean velocity ( $U$ ) at a location. High TI indicates elevated $k$ along with increased residence time ( $1/U$ ).	(41)
Specific dissipation rate ( $\omega$ )	$\omega = \frac{k^{1/2}}{C_\mu^{1/4} \ell}$ where $C_\mu = 0.09$	$1/\text{s}$	Proportional to integral shear strain rate ( $\dot{\gamma}$ ) proposed by Finlay (59). Current interpretation (16, 59) is a measure of the velocity gradient across the integral scale eddies.	Similar to Finlay (59) and Coates et al. (16)
Non-dimensional specific dissipation rate (NDSD)	$\text{NDSD} = \frac{\bar{\omega} \cdot t_{\text{exp}}}{Q}$	Non-dimensional	Both $\omega$ and exposure time to turbulence directly influence deagglomeration. The $\bar{\omega}$ is the volume-averaged specific dissipation rate. Exposure time ( $t_{\text{exp}}$ ) is based on approximate volume ( $V \approx 1 \text{ cm}^3$ ) and flow rate ( $Q$ ).	New parameter
<b>Particle-based</b>				
Wall impactions without restitution ( $\text{Imp}_{e=0}$ )	Percentage of particles contacting the wall vs. number injected	Non-dimensional (%)	The number of wall hits may describe the potential for deagglomeration based on impaction with device surfaces. The restitution coefficient ( $e$ ) is set to zero to simulate no bounce.	(14, 16)
Wall impactions with perfect restitution ( $\text{Imp}_{e=1}$ )	Percentage of particles contacting the wall vs. number injected	Non-dimensional (%)	Large particles may hit the wall multiple times causing continued deaggregation. The restitution coefficient ( $e$ ) is set to 1 to simulate full bounce.	(16, 18)
Average trajectory integral of $k \cdot dt$ ( $k_{\text{avg}}$ )	$\int_{\text{trajectory}} k \cdot dt$	$\text{N} \cdot \text{m}$ (or J)	Represents the product of $k$ and $dt$ a particle experiences over its trajectory through the system. Both $k$ and exposure time to $k$ are expected to be directly proportional to deaggregation. Units represent work (J) performed by turbulence on particle.	New parameter
Average trajectory integral of $\omega \cdot dt$ ( $\omega_{\text{avg}}$ )	$\int_{\text{trajectory}} \omega \cdot dt$	Non-dimensional	Represents the product of $\omega$ and $dt$ a particle experiences over its trajectory through the system. Both $\omega$ and exposure time to $\omega$ are expected to be directly proportional to deaggregation.	New parameter

slower local mean velocity will increase exposure time to  $k$  and hypothetically increase the deaggregation. In turbulence, the specific dissipation rate is typically defined as (41)

$$\omega = \frac{k^{1/2}}{C_\mu^{1/4} \ell} \quad [s^{-1}] \quad (2)$$

where  $k$  has units of  $m^2/s^2$ ,  $C_\mu$  is a constant equal to 0.09, and  $\ell$  is the characteristic eddy length scale [m]. The  $\omega$  parameter captures both kinetic energy available for breakup along with eddy length scale, with smaller eddies hypothetically being more effective at breaking up small aggregates and increasing FPF. Differences between this view and that of previous studies are described in the Discussion.

For the inhalers, volume-averaged values are calculated to provide a single number for quantification and correlation development. Considering  $\omega$  as an example, the volume-averaged specific dissipation is calculated as

$$\bar{\omega} = \frac{1}{V} \int_V \omega_{CV} dV \quad [1/s] \quad (3)$$

where  $V$  is the volume of the airflow passage and  $\omega_{CV}$  is the local  $\omega$  value in individual voxels, or control volumes (CVs), composing the geometry. It is also reasonable that exposure time to  $\bar{\omega}$  increases the amount of agglomerate breakup, and is calculated as

$$t_{\text{exposure}} = \frac{V}{Q} \quad [s] \quad (4)$$

where  $Q$  is flow rate through the airflow passage and  $V$  is an approximate passage volume (taken to be  $1 \text{ cm}^3$  in Eq. 4). The non-dimensional specific dissipation is then developed as

$$NDSD = \bar{\omega} t_{\text{exposure}} \quad (5)$$

This parameter captures both the strength of the turbulence most responsible for aerosol breakup ( $\bar{\omega}$ ) as well as the exposure time to  $\bar{\omega}$ . In reporting volume-averaged values in the Results, the over-bar convention is dropped for convenience. In this study, parameters are only considered in the flow passage downstream of the capsule dispersion chamber. This is justified by using the same capsule chamber in all inhalers considered.

Particle-based parameters in this study seek to capture both particle-wall interactions as well as trajectory path integrated turbulence quantities. Wall impactions with the assumption of no bounce (zero restitution;  $e = 0$ ) are symbolized as  $\text{Imp}_{e=0}$ . However, particle-wall contact and rebound are considered effective deaggregation mechanisms in carrier-based and agglomerate DPI systems (17, 18). To simulate this condition, a limiting case was considered in which all particles hitting the wall rebound from the surface

without energy loss (*i.e.*, with a restitution coefficient of  $e=1$ ), symbolized by  $\text{Imp}_{e=1}$ . Both  $\text{Imp}_{e=0}$  and  $\text{Imp}_{e=1}$  are calculated as the number of wall hits divided by the number of inlet particles (6,000) and multiplied by 100 to form a percentage.

Integrals of  $k$  and  $\omega$  were also taken along trajectories of particles and averaged over all 6,000 injections. For an individual trajectory and turbulent kinetic energy, the trajectory integral is

$$\int_{\text{trajectory}} k \cdot dt \quad (6)$$

which represents both kinetic energy and exposure time. The units of  $k \cdot dt$  are Joules, which represents work performed on the aerosol by turbulent fluctuations. The over-bar on this term in Table II denotes an average value of  $k$  taken over all 6,000 injections, which is symbolized as

$$\bar{k}_{\text{avg}} = \overline{\int_{\text{trajectory}} k \cdot dt} \quad (7)$$


Similarly for  $\omega$ , the integration of  $\omega \cdot dt$  represents both the value of  $\omega$  and exposure period, and forms a non-dimensional number ( $I\omega_{\text{avg}}$ ). Both of these trajectory integral parameters along with NDSD are newly proposed for potentially correlating with aerosol deaggregation and will be evaluated for the first time in this study.

## RESULTS

### Flow-Based Factors

Velocity contours along the midplane and at cross-sectional locations for each inhaler are provided in Fig. 2 as a representation of the flow field and flow-based parameters. Symmetric flow in the deaggregation passage are observed for Inhalers 1 and 2. However, asymmetrical boundary layer separation and recirculation within the flow pathway is observed in Inhalers 3, 4, and 6. This recirculation reduces the effective diameter of the passage, as described by Longest and Hindle (14). While reduced effective diameters were found to impede the performance of spray inhalers, the associated increase in turbulence may improve the performance of DPI aerosols in terms of particle deaggregation and FPFs. The observed recirculation regions are a transient feature which oscillate periodically from one side of the flow passage to the other. The 3D grid geometry (Inhaler 5) appears to unify the exiting flow field, much like a flow straightener in turbulence control. The uniformity of the flow through the downstream passage of Inhaler 5 may be the result of increased small scale turbulence. For Inhaler 6, the 3D array is observed to operate as designed with elevated flow between rods impacting on the

**Fig. 2** Contours of velocity magnitude at the midplane and cross-sectional locations for (a) Inhaler 1 at 45 LPM, (b) Inhaler 2 at 45 LPM, (c) Inhaler 3 at 45 LPM, (d) Inhaler 4 at 75 LPM, (e) Inhaler 5 at 45 LPM, and (f) Inhaler 6 at 45 LPM.



staggered rods in the next row. Moreover, the elevated velocities in the 2nd row are greater than the elevated velocities in the first row indicating the potential for turbulence amplification in the 3D array.

Values of the flow-based factors are presented for the eight inhalers, some at multiple flow rates, in Table III based on the definitions provided in Table II. Table III also provides the experimentally determined MMD values, as well as FPFs, for each inhaler and flow rate combination. Based on the experimental results, Inhaler 6 at 45 and 60 LPM provides the best performance in terms of the lowest MMD with values of  $0.98 \mu\text{m}$  and  $1.03 \mu\text{m}$ , respectively. The largest aerosols in terms of MMD are created by Inhalers 1 (MMD =  $1.35 \mu\text{m}$ ) and Inhaler 3 (MMD =  $1.36 \mu\text{m}$ ), which are the constricted

tube and 2D mesh designs, respectively. Both the constricted tube and 2D mesh are common features in current inhalers as a means to increase turbulence and FPF (3, 58).

Quantitative correlations between the experimentally determined MMD and CFD predicted flow-based parameters are presented in Fig. 3. As expected from the similar MMD results at two flow rates with Inhaler 6, no correlation is observed between Q and MMD when all eight inhalers are considered. A weak association is observed between MMD and pressure drop in the flow passage with a coefficient of determination  $R^2 = 0.38$ . However, the correlation fails to capture formation of the smallest aerosol in the series. Similarly, a weak association is observed between input power and MMD that also misses the best performing case.

**Table III** Key Flow-Based Factors Expected to Influence Deagglomeration


Inhaler number and flow rate <sup>a</sup>	Q (m <sup>3</sup> /s)	$\Delta P^b$ (Pa)	Power (W)	$\tau_s$ (N/m <sup>2</sup> )	MMD <sup>c</sup> ( $\mu$ m)	FPF <sub>1 <math>\mu</math>m/ED</sub> (%) <sup>d</sup>	FPF <sub>5 <math>\mu</math>m/ED</sub> (%) <sup>e</sup>
1 at 45 LPM	$7.5 \times 10^{-4}$	921.8	0.691	0.707	1.35 (0.02) <sup>f</sup>	18.8 (0.5) <sup>f</sup>	89.5 (3.2) <sup>f</sup>
2 at 45 LPM	$7.5 \times 10^{-4}$	667.7	0.501	1.10	1.21 (0.1)	26.8 (3.8)	95.8 (0.05)
3 at 45 LPM	$7.5 \times 10^{-4}$	1421.6	1.07	1.23	1.36 (0.07)	19.2 (4.7)	94.5 (2.6)
4 at 60 LPM	$1.0 \times 10^{-3}$	934.0	0.934	5.16	1.27 (0.07)	23.6 (3.4)	91.2 (2.1)
4 at 75 LPM	$1.25 \times 10^{-3}$	2004.5	2.51	11.0	1.27 (0.14)	26.9 (6.0)	95.9 (0.7)
5 at 45 LPM	$7.5 \times 10^{-4}$	758.6	0.569	1.16	1.31 (0.03)	20.4 (2.7)	95.5 (1.1)
6 at 45 LPM	$7.5 \times 10^{-4}$	1902.0	1.43	2.17	0.98 (0.04)	38.8 (6.3)	97.3 (0.3)
6 at 60 LPM	$1.0 \times 10^{-3}$	3063.9	3.06	2.85	1.03 (0.05)	35.2 (1.3)	97.3 (0.4)
7 at 45 LPM	$7.5 \times 10^{-4}$	950.4	0.713	1.21	1.28 (0.03)	23.0 (1.7)	97.4 (0.3)
8 at 45 LPM	$7.5 \times 10^{-4}$	775.5	0.582	1.23	1.18 (0.06)	28.1 (2.6)	94.6 (0.8)

<sup>a</sup> Denotes inhaler number and flow rate (LPM)<sup>b</sup> Pressure drop over the internal flow passage starting at the exit of the capsule chamber<sup>c</sup> Estimated based on measured MMAD and the skeletal density of the primary particles ( $\rho_p = 1.325 \text{ g/cm}^3$ )<sup>d</sup> Fine particle fraction (% < 1  $\mu$ m) of the emitted dose (ED)<sup>e</sup> Fine particle fraction (% < 5  $\mu$ m) of the emitted dose (ED)<sup>f</sup> Standard deviations (SD) of experimental results based on  $n \geq 3$  trials

Interestingly, this result indicates that effective breakup of the aerosol requires more than just increased power supplied to the inhaler. Therefore, an effectively designed inhaler can produce a reduced MMD compared with an inefficient design at the same or reduced power input and pressure drop. Surprisingly, no association was observed between MMD and turbulent shear stress, as defined in Table II, for a

carrier-free powder. Overall, quantitative correlations between flow-based parameters and performance over the set of eight inhalers appear relatively weak and strongest for  $\Delta P$  and power.

Experimentally determined values of FPF<sub>1  $\mu$ m/ED</sub> and FPF<sub>5  $\mu$ m/ED</sub> are presented in Table III and rank similarly compared with the respective MMD values. Figure 4 presents



**Fig. 3** Quantitative comparison of CFD predicted flow-based parameters with experimentally determined MMD of the aerosol. Flow-based parameters include (a) flow rate (Q), (b) pressure drop ( $\Delta P$ ), (c) Power, and (d) shear stress ( $\tau_s$ ). Error bars denote  $\pm$  one standard deviation in the experiments.

quantitative comparisons between the MMD and FPF values for all inhalers considered. Most likely because of the relatively small aerosol size,  $FPF_{1\text{ }\mu\text{m/ED}}$  is found to correlate most closely with MMD ( $R^2 = 0.97$ ). A much weaker correlation is observed between  $FPF_{5\text{ }\mu\text{m/ED}}$  and MMD ( $R^2 = 0.32$ ). The strong correlation between  $FPF_{1\text{ }\mu\text{m/ED}}$  and MMD with a weaker correlation between MMD and FPF verifies the expected trend for this relatively small aerosol. The primary focus of this study is to generate aerosols in the range of  $1\text{ }\mu\text{m}$  and below for next-generation DPI applications. Therefore, correlation development in this study is focused primarily on MMD and  $FPF_{1\text{ }\mu\text{m/ED}}$ . However, it is observed that the  $FPF_{5\text{ }\mu\text{m/ED}}$  values (89.5–97.4%) are exceptionally high compared with existing devices (3, 58).

### Turbulence-Based Factors

The newly proposed NDSD factor is presented as a representative turbulence-based parameter for the eight inhalers at characteristic flow rates in Fig. 5. Increased NDSD values are observed in the center of the flow field for Inhalers 3–6. Compared with the 2D mesh, the 3D grid appears to extend the region of elevated NDSD values further into the downstream flow field. The 3D array provides an even larger region of elevated NDSD values. In contrast, both Inhalers 1 and 2 maintain elevated NDSD values only near the walls where interactions with particles is less likely. While turbulence may be highest in Inhaler 4 in terms of  $k$  and  $TI$  (Table IV), the reduced residence time associated with the higher flow rates produces a much lower value of NDSD, which is consistent with the mid-level value of MMD =  $1.27\text{ }\mu\text{m}$  for this inhaler. The NDSD is maximum for Inhaler 6 at 45 LPM, which correlates well with the minimum MMD value of  $0.98\text{ }\mu\text{m}$  (Table IV).

Considering quantitative correlations for turbulence-based parameters (Fig. 6), only a weak and inconsistent relationship is observed between  $k$  and MMD. A much stronger correlation with  $k$  may be obtained if Inhaler 4 is removed. However the goal is to establish an aerodynamic


factor that is predictive of performance across a range of inhalers and deaggregation devices. Similarly for  $TI$ , a relatively weak correlation is obtained overall. However in the case of  $TI$ , removing Inhalers 3, 4, 5, and 7 would significantly strengthen the relationship. The specific dissipation rate  $\omega$  is observed to quantitatively predict MMD to a high degree with an  $R^2 = 0.66$  for all inhalers. However, this correlation is again inaccurate for the case of minimum MMD. The correlation with  $\omega$  is further strengthened by incorporating the residence time to form the NDSD parameter, which has an  $R^2 = 0.8$  across all eight inhalers and captures both the maximum and minimum MMD values observed in the experiments.

Based on the strength of the correlation between NDSD and MMD, Fig. 7 presents correlations between NDSD and FPF values (reported in Table IV). As expected, the NDSD parameter is observed to be highly predictive of  $FPF_{1\text{ }\mu\text{m/ED}}$  with an  $R^2$  value of 0.79 (Fig. 7a). The NDSD factor also captures the trend of the  $FPF_{5\text{ }\mu\text{m/ED}}$  data (Fig. 7b); however, the coefficient of determination is  $R^2 = 0.31$ . This weak quantitative relationship is expected considering that MMD did not strongly correlate with  $FPF_{5\text{ }\mu\text{m/ED}}$ . As with MMD, correlations between  $\omega$  and FPFs were strong but had  $R^2$  values below the NDSD parameter (not shown) for all eight inhalers considered.

### Particle-Based Factors


Trajectories colored according to the path integral of  $\omega dt$  are presented in Fig. 8 for Inhalers 3–6. As expected, trajectory integral values are observed to increase significantly in the region of the 2D mesh, inward jets, 3D grid, and 3D array. Subsequent slower increases in values are then observed downstream. Trajectories are observed to experience some turbulent dispersion in the high turbulence regions. For all inhalers, significantly elevated values of the  $\omega dt$  parameter are observed near the wall.

Considering quantitative correlations for particle-based parameters (Fig. 9), weak to negligible associations were



**Fig. 4** Quantitative comparison of MMD with (a) fine particle fraction less than  $1\text{ }\mu\text{m}$  of the emitted dose ( $FPF_{1\text{ }\mu\text{m/ED}}$ ) and (b) fine particle fraction less than  $5\text{ }\mu\text{m}$  of the emitted dose ( $FPF_{5\text{ }\mu\text{m/ED}}$ ) based on experimental data. Error bars denote  $\pm$  one standard deviation in the experiments.

**Fig. 5** Contours of non-dimensional specific dissipation (NDS) at the midplane and cross-sectional locations for (a) Inhaler 1 at 45 LPM, (b) Inhaler 2 at 45 LPM, (c) Inhaler 3 at 45 LPM, (d) Inhaler 4 at 75 LPM, (e) Inhaler 5 at 45 LPM, and (f) Inhaler 6 at 45 LPM.



observed between the particle parameters and MMD. Due to no apparent correlation, not all cases were considered for the impaction studies. The strongest association was observed between the  $I\omega_{avg}$  parameter and MMD with an  $R^2$  of 0.24. However, this relationship did not capture the best performing case of Inhaler 6 and demonstrates an inconsistent trend.

### Analysis at Constant Pressure Difference

Results for a constant pressure difference of 2 kPa across the flow passages are illustrated in Fig. 10. Figure 10a presents a comparison of the MMD correlation based on NDS (solid line from Fig. 6(d) along with new experimental data for

Inhaler 3 considered at 2 kPa. As observed from the figure, the correlation agrees with the new experimental data point within the relative bounds of expected difference associated with an of  $R^2 = 0.8$ . The MMD for Inhaler 6 at 2 kPa is also presented, based on CFD simulations. New experiments are not required for Inhaler 6 at 2 kPa because this pressure drop is bracketed by values for 45 and 60 LPM (Table III), which did not change the MMD significantly in the experiments and agrees with the correlation value. This comparison shows that even at the same pressure drop, the 3D rod array (Inhaler 6) produces a lower MMD compared with the 2D grid (Inhaler 3).

A comparison of all eight inhalers at a simulated airflow passage pressure drop of 2 kPa is presented in


**Table IV** Key Turbulence-Based Factors Expected to Influence Deagglomeration

Inhaler number and flow rate <sup>a</sup>	$k^b$ ( $\text{m}^2/\text{s}^2$ )	$\pi^b$ (%)	$\omega^b$ (1/s)	NDSD <sup>b</sup> (dimensionless)	MMD <sup>c</sup> ( $\mu\text{m}$ )
1 at 45 LPM	4.2	13.5	61,949	82.6	1.35 (0.02) <sup>d</sup>
2 at 45 LPM	5.6	20.1	111,303	148.4	1.21 (0.1)
3 at 45 LPM	12.1	47.2	64,846	86.5	1.36 (0.07)
4 at 60 LPM	143.0	35.3	96,020	96.0	1.27 (0.07)
4 at 75 LPM	474.2	50.5	132,866	106.3	1.27 (0.14)
5 at 45 LPM	9.5	38.3	72,673	96.9	1.31 (0.03)
6 at 45 LPM	19.1	26.03	127,277	169.7	0.98 (0.04)
6 at 60 LPM	28.3	23.9	148,323	148.3	1.03 (0.05)
7 at 45 LPM	10.0	30.7	75,565	100.8	1.28 (0.03)
8 at 45 LPM	6.7	22.2	115,799	154.4	1.18 (0.06)


<sup>a</sup> Denotes inhaler number and flow rate (LPM)<sup>b</sup> Volume-averaged quantities within the flow passage of each inhaler<sup>c</sup> Estimated based on measured MMAD and the skeletal density of the primary particles ( $\rho_p = 1.325 \text{ g/cm}^3$ )<sup>d</sup> Standard deviations (SD) of experimental results based on  $n \geq 3$  trials

Fig. 10b. The solid line is the MMD *vs.* NDSD correlation from Fig. 6d. Data points indicate CFD predicted values of NDSD for each inhaler at a 2 kPa pressure drop with MMD values provided from the correlation. Again, Inhaler 6 provides the minimum MMD and Inhaler 1 produces the maximum MMD. For the 3D array, reducing the rod diameters (Inhaler 8) and increasing the cross-sectional area of the array region

(Inhaler 7) both increase MMD of the aerosol. The 3D grid (Inhaler 5) produces a similar MMD compared with the 2D mesh (Inhaler 3) and a larger MMD than the 3D array (Inhaler 6) at the same pressure drop. As a result of this analysis, the 3D array design appears to provide superior performance compared with both existing deaggregation designs and other new 3D options evaluated at the same pressure drop.



**Fig. 6** Quantitative comparison of CFD predicted turbulence-based parameters with experimentally determined MMD of the aerosol. Turbulence-based parameters include **(a)** turbulent kinetic energy ( $k$ ), **(b)** turbulent intensity (TI), **(c)** specific dissipation rate ( $\omega$ ), and **(d)** non-dimensional specific dissipation (NDSD). Error bars denote  $\pm$  one standard deviation in the experiments.




**Fig. 7** Quantitative comparison of CFD predicted NDSD with experimentally determined (a) FPF<sub>1 μm/ED</sub> and (b) FPF<sub>5 μm/ED</sub>. Error bars denote  $\pm$  one standard deviation in the experiments.


## DISCUSSION

A primary outcome of this study is that not all aerodynamic factors associated with deaggregation quantitatively correlate with MMD and FPF for a carrier-free formulation. Previous studies of carrier-free DPIs, and some carrier-based systems, have associated turbulence with the deaggregation of aerosols (13, 15, 23, 24). As described by Finlay (59) and Coates *et al.* (16), both the turbulent energy and length scale are important for deaggregation. Considering only  $k$  or  $Tl$  ignores the length scale of turbulence and, therefore, does not correlate well with deaggregation across a series of multiple inhalers. It is observed that an advantage of the current study compared with previous studies is the large number of inhalers considered.

Selection of 3 or 4 of the designs would have resulted in very strong correlations between deaggregation and  $k$  or  $Tl$ . Similarly, shear stress was not found to correlate with deaggregation, based on a definition that included CFD volume averaging of the eddy dissipation rate (Table II). In one of the only other existing quantitative correlations for deaggregation, Xu *et al.* (11, 21, 22) established very strong relationships between  $\tau_s$  and FPF for carrier-based formulations within well defined sets of entrainment tubes. Reasons that  $\tau_s$  does not work well in the current study include a different formulation type, *i.e.*, carrier-free, consideration of multiple inhalers, and potentially calculation of  $\tau_s$  based on CFD estimates of  $\epsilon$  instead of analytical estimates. This study provides further evidence that deaggregation of carrier-free powders occurs

**Fig. 8** Trajectories of 1 μm particles colored according to the path integral of  $\omega \cdot dt$  for (a) Inhaler 3 at 45 LPM, (b) Inhaler 4 at 75 LPM, (c) Inhaler 5 at 45 LPM, and (d) Inhaler 6 at 45 LPM.






**Fig. 9** Quantitative comparison of CFD predicted particle-based parameters with experimentally determined MMD of the aerosol. Particle-based parameters include (a) wall impactions with zero restitution ( $\text{Imp}_{e=0}$ ), (b) wall impactions with perfect restitution ( $\text{Imp}_{e=1}$ ), (c) average trajectory integral of  $k \cdot dt$  ( $lk_{\text{avg}}$ ), and (d) average trajectory integral of  $\omega \cdot dt$  ( $l\omega_{\text{avg}}$ ). Error bars denote  $\pm$  one standard deviation in the experiments.

by a different mechanism than with carrier-based and large agglomerate formulations. As described in the [Introduction](#) section, deaggregation of carrier-based formulations was previously associated with turbulence (13), turbulent shear stress (11, 21, 22), and wall impactions of particles (18) while deaggregation of large agglomerates was associated primarily with wall impactions (17). Interestingly,  $\Delta P$  and power showed weak but reasonable correlations with MMD. However, these relations failed to characterize the performance of the best inhalers considered in this study. This inconsistency indicates quantitatively that effective deaggregation cannot be achieved by simply maximizing the power delivered to the inhaler. An

efficient inhaler can be developed that produces higher FPFs and lower MMDs for the same formulation at lower  $\Delta P$  and power inputs compared with an inefficient design (Fig. 3). An aerodynamic factor that can predict performance is then needed for device optimization that can be used to maximize deaggregation for a set pressure drop or power input.

For the carrier-free leucine combination particle formulation considered in this study, turbulence interaction with the aerosol appears to be the primary particle breakup mechanism. Particle impactions and flow rate (which affects particle impaction velocity) showed no association with the MMD across the inhalers. Of the turbulence-based factors



**Fig. 10** Quantitative comparison of MMD vs. NDSD at a consistent  $\Delta P$  of 2 kPa through the flow passage. (a) The NDSD correlation (solid line) is in reasonable agreement with the experimentally determined performance of Inhaler 3 and indicates that the 3D array produces a smaller aerosol than the 2D mesh at the same pressure drop. (b) Evaluation of all inhalers based on the NDSD correlation (solid line) indicating that Inhaler 6 provides the lowest MMD for a  $\Delta P$  of 2 kPa.

considered, the newly proposed NDSD parameter performed best with a coefficient of determination of approximately  $R^2 = 0.8$  for both MMD and  $\text{FPF}_{1\text{ }\mu\text{m}/\text{ED}}$ . This parameter is designed to account for three aspects of the interaction between the particles and turbulence. These aspects are (i) strength of the turbulence represented by turbulent kinetic energy, (ii) inverse characteristic length scale of the turbulence represented by  $1/\ell$ , and (iii) time available for particle-turbulence interactions. Clearly, stronger turbulence will be more effective at breaking apart aggregates resulting in a direct association with  $k$ . The  $1/\ell$  term indicates that smaller energetic eddies are more efficient at producing small particles compared with large eddies. That is, the most effective turbulence for creating small particles has high energy in the small eddies. Finally, it is reasonable that increasing the exposure time to  $k/\ell$  will increase the amount of deaggregation that occurs. The composite NDSD term incorporates these three aspects of turbulent-particle interaction into a convenient non-dimensional form that demonstrates the strongest correlation with deaggregation observed in this study.

The NDSD factor is based on  $\omega$ , which is proportional to the  $\dot{\gamma}$  or integral scale strain rate (ISSR) [1/s] term described by Finlay (59) and Coates *et al.* (15, 16, 23). However, there are two important differences between the NDSD factor and these previous studies. First, the NDSD parameter incorporates a residence time term that was very important in explaining the reduced inhaler performance occurring in some cases when the flow rate and  $\omega$  parameters increased. This residence time theory may also be useful in interpreting previous results where increases in flow rate did not improve aerosol performance (23). Second, the current study interprets the  $\omega$  term, and therefore the type of turbulence that leads to effective deaggregation, different from other studies. Finlay (59) and Coates *et al.* (16) emphasize that the integral scale eddies have maximum energy, are the largest of the flow field, and are most responsible for breakup of the aerosol. In contrast, the current study interprets the definition of  $\omega$  (Eq. (2)) to imply that  $\ell$  should be minimized for effective deaggregation. Hence, the most effective production of small particles occurs when high turbulent energy ( $k$ ) is contained in small eddies. Efficient inhalers should then seek to maximize  $k$  but also minimize the length scale of the turbulence in order to produce the highest possible FPFs.

The particle-based integrations of turbulent quantities were not strongly associated with deaggregation. The trajectory integral of  $k$  incorporates the residence time but ignores the turbulence length scale. The trajectory integral of  $\omega$  showed some agreement with MMD, but was not as strongly correlated as the volume averages of  $\omega$  and NDSD. It was found that the trajectory integral average values were influenced by near-wall particles that had very large values of both  $\omega$  and  $dt$ . These large values tended to dominate the final average value in a manner that was not representative of what most particles experienced in the central portion of

the flow. A limit to the integral value along individual pathways may solve this problem. However, determining the physically relevant maximum value of  $\omega \cdot dt$  along a trajectory would be difficult. Large values of near-wall integrals also made it very difficult to obtain particle number independent results with high relative errors observed through 50,000 trajectories. Considering these limitations and the strength of the volume-averaged correlations, the latter approach is recommended for future design studies with carrier-free formulations.

In order to analyze the complex phenomenon of deaggregation, multiple approaches can be implemented. If the focus of a study is the deaggregation of different powder formulations, then it is critical to base the analysis on a single geometry or set of controlled geometries as described by Xu *et al.* (11, 21, 22). To analyze the effects of different aerodynamic mechanisms on deaggregation, a single formulation is needed along with either devices to isolate individual factors or more complex inhaler flow passages combined with CFD analysis. Voss and Finlay (13) employed the approach of designing a test apparatus to isolate individual deaggregation mechanisms. While scientifically elegant, it is very difficult to isolate individual mechanisms affecting deaggregation due to factor dependence and complex flow interrelations. For example, increasing turbulence will also increase wall impactions due to the turbulent dispersion of particles. Meshes to increase impaction will also modify the turbulence length scale, which was found to be important for aggregate breakup. In the current study, realistic flow passages were considered to form eight different inhalers, some considered at multiple flow rates, along with CFD analysis. In each inhaler, multiple deaggregation mechanisms are likely occurring. Given the complexity of these systems and the deaggregation process, it is not surprising that few successful quantitative correlations were found when considering individual variables. Interestingly, the NDSD parameter emerged as providing the strongest quantitative correlation with the MMD and  $\text{FPF}_{1\text{ }\mu\text{m}/\text{ED}}$ , which were the markers for deaggregation. Other factors are likely occurring in each inhaler and contributing to deaggregation, such as wall impactions in Inhaler 6, but these parameters are either somewhat proportional to the turbulence and NDSD (as with particle impactions and turbulent shear stress) or provide a secondary breakup mechanism. While these multiple deaggregation mechanisms may be occurring, the NDSD was found to be the primary quantifiable factor correlating with deaggregation across multiple platforms, which can now be used in future flow passage and design optimization studies of inhalers delivering carrier-free formulations.

In a previous study, Son *et al.* (35) demonstrated that the 3D rod array design exhibited superior performance to a 2D mesh and the base HandiHaler DPI at a consistent flow rate. However, it was not obvious from Son *et al.* (35) why the 3D array performed better than the other designs and if this

improved performance would be maintained at an identical pressure drop. The current analysis proposes the NDSD as the primary factor for carrier-free deaggregation and indicates that the 3D rod array design is effective because it maximizes NDSD. Specifically, the velocity field plots (Fig. 2) indicate that the rod array amplifies velocity and turbulence, or  $k$ , as velocities were highest between the 2nd and potentially 3rd rows of rods. The spacing between the rods serves to control the turbulence length scale, with each successive row of rods further reducing  $\ell$  as eddies are formed and then broken into smaller components through rod and eddy interactions. Finally, the 3D configuration increases the length of the high turbulence zone thereby maximizing exposure time of the particles. This rod array may also be effective at breaking apart larger aggregates, but the mechanism of action will likely shift to a combination of impaction and turbulent interaction. Furthermore, the 3D rod array is not likely to clog when presented with larger powder or agglomerate doses. Considered at a constant pressure drop of 2 kPa over the flow passage, the 3D array was again determined to maximize the NDSD value, which correlates with maximum FPF and minimum MMD.

One potential limitation of this study is the CFD analysis of only the flow passage and not the upstream capsule dispersion chamber. Previous studies have demonstrated that significant turbulence and other flow features are generated in the capsule chamber and propagated into the downstream flow passage (18, 60). Longest and Hindle (14) previously showed that by changing the air inlet size of an inhaler, turbulence levels throughout the device were significantly modified, which had an impact on mouthpiece drug retention. In the current study, the same capsule chamber was used for all eight inhalers considered in the experiments. The CFD simulations implemented the same inlet boundary conditions to the flow passages. The results of this study then provide the relative differences in the aerodynamic factors based entirely on flow passage design. Considering that relative comparisons are made with the same inlet conditions, it is not necessary to include the upstream capsule chamber in the CFD simulations. However, exact values of the aerodynamic factors may change if the capsule dispersion chamber is included in the simulations. Therefore, the correlations developed are intended to demonstrate strengths of association and provide guidance for designing effective flow passages for deaggregation, as with the 3D rod array. Clearly, performance of the different inhalers considered will change if different capsule dispersion chambers are employed.

## CONCLUSIONS

In conclusion, this study has evaluated associations between aerodynamic parameters and DPI performance for a

carrier-free formulation with the goal of forming micrometer and submicrometer aerosols for EEG and other next-generation respiratory drug delivery approaches. The number of inhalers and number of aerodynamic parameters were both significantly greater than have been considered in any previous study of this type. For the carrier-free formulation considered, turbulence was identified as the primary deaggregation mechanisms of the particles. Of the 12 aerodynamic factors considered, the newly proposed NDSD showed the strongest correlation with both MMD and FPF. Factors that were determined to be important for turbulent deaggregation of the aerosol and quantified by the NDSD parameter were high turbulent kinetic energy and exposure time and small characteristic eddy length scales. The newly proposed 3D rod array design was found to have the highest NDSD values based on CFD simulations and the lowest MMD based on *in vitro* experiments evaluated at both consistent flow rates and pressure drops. The 3D rod array was capable of creating an aerosol with a MMD < 1  $\mu\text{m}$ , and with FPF<sub>1  $\mu\text{m}/\text{ED}$</sub>  and FPF<sub>5  $\mu\text{m}/\text{ED}$</sub>  values of 38.8 and 97.3%, respectively. Existing DPI analyses typically ignore FPF<sub>1  $\mu\text{m}/\text{ED}$</sub>  and report FPF<sub>5  $\mu\text{m}/\text{ED}$</sub>  in the range of 40%. These results indicated that forming submicrometer aerosols with passive DPIs is practical for EEG and other next-generation respiratory drug delivery strategies. Furthermore, the 3D rod array design is highly configurable and can be adjusted to maximize NDSD for optimized performance. Future studies are needed to evaluate the NDSD parameter with different initial aerosolization mechanisms and with different formulations, and to apply this newly developed parameter to improve the performance of existing DPIs and newly proposed submicrometer inhalers.

## ACKNOWLEDGMENTS AND DISCLOSURES

This study was supported by Award Number R21 HL104319 and R01 HL107333 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.

## REFERENCES

1. Smith IJ, Bell J, Bowman N, Everard M, Stein S, Weers JG. Inhaler devices: what remains to be done? *J Aerosol Med Pulm Drug Deliv.* 2010;23:S25–37.
2. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. *Respir Med.* 2002;96:293–304.
3. Islam N, Cleary MJ. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - A review for multidisciplinary researchers. *Med Eng Phys.* 2012;34:409–27.

4. Byron PR. Drug delivery devices: issues in drug development. *Proc Am Thorac Soc.* 2004;1:321–8.
5. Borgstrom L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. *J Aerosol Med.* 2006;19:473–83.
6. Scheuch G, Bennett W, Borgstrom L, Clark A, Dalby R, Dolovich M. Deposition, imaging, and clearance: what remains to be done? *J Aerosol Med Pulm Drug Deliv.* 2010;23:S39–57.
7. Delvadia R, Hindle M, Longest PW, Byron PR. *In vitro* tests for aerosol deposition. II: IVIVCs for different dry powder inhalers in normal adults. *J Aerosol Med Pulm Drug Deliv.* 2012. doi:10.1089/jamp.2012.0975.
8. Longest PW, Tian G, Walenga RL, Hindle M. Comparing MDI and DPI aerosol deposition using *in vitro* experiments and a new stochastic individual path (SIP) model of the conducting airways. *Pharm Res.* 2012;29:1670–88.
9. Chan H-K. Dry powder aerosol drug delivery - Opportunities for colloid and surface scientists. *Colloids Surf A: Physicochem Eng Aspects.* 2006;284–285:50–5.
10. Chan H-K. Dry powder aerosol delivery systems: current and future research directions. *J Aerosol Med.* 2006;19(1):21–7.
11. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance. *J Pharm Sci.* 2010;99:3442–61.
12. Wong W, Fletcher DF, Traini D, Chan HK, Young PM. The use of computational approaches in inhaler development. *Adv Drug Deliv Rev.* 2012;64:312–22.
13. Voss AP, Finlay WH. Deagglomeration of dry powder pharmaceutical aerosols. *Int J Pharm.* 2002;248:39–40.
14. Longest PW, Hindle M. Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths. *J Aerosol Med Pulm Drug Deliv.* 2009;22:271–83.
15. Coates MS, Chan H-K, Fletcher DF, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. *J Pharm Sci.* 2006;95:1382–92.
16. Coates MS, Fletcher DF, Chan H-K, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length. *J Pharm Sci.* 2004;93:2863–76.
17. Wong W, Fletcher DF, Traini D, Chan HK, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems. *J Pharm Sci.* 2011;100:2744–54.
18. Donovan MJ, Kim SH, Raman V, Smyth HD. Dry powder inhaler device influence on carrier particle performance. *J Pharm Sci.* 2011;101:1097–107.
19. Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition *in vitro*. *Eur J Pharm Sci.* 1998;7:73–80.
20. Louey MD, VanOort M, Hickey AJ. Standardized entrainment tubes for the evaluation of pharmaceutical dry powder dispersion. *J Aerosol Sci.* 2006;37:1520–33.
21. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate. *J Pharm Sci.* 2010;99:3398–414.
22. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate. *J Pharm Sci.* 2010;99:3415–29.
23. Coates MS, Chan H-K, Fletcher DF, Raper JA. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. *Pharm Res.* 2005;22:1445–53.
24. Coates MS, Chan H-K, Fletcher DF, Chiou H. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhalation. *Pharm Res.* 2007;24:1450–6.
25. Wong W, Fletcher DF, Traini D, Chan HK, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. *Pharm Res.* 2010;27:1367–76.
26. Wong W, Fletcher DF, Traini D, Chan HK, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems. *J Pharm Sci.* 2011;100:4710–21.
27. Adi S, Tong ZB, Chan HK, Yang RY, Yu AB. Impact angles as an alternative way to improve aerosolisation of powders for inhalation? *Eur J Pharm Sci.* 2010;41:320–7.
28. Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? *J Aerosol Med Pulm Drug Deliv.* 2010;23:S5–S23.
29. Yang JZ, Young AL, Chiang PC, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. *J Pharm Sci.* 2008;97:4869–78.
30. El-Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. *J Pharm Sci.* 2009;98:2731–46.
31. Longest PW, Tian G, Li X, Son Y-J, Hindle M. Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways. *Ann Biomed Eng.* 2012;40:2596–610.
32. Longest PW, Hindle M. Condensational growth of combination drug-excipient submicrometer particles: comparison of CFD predictions with experimental results. *Pharm Res.* 2012;29:707–21.
33. Longest PW, Hindle M. Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols. *Aerosol Sci Technol.* 2011;45:884–99.
34. Hindle M, Longest PW. Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: evaluation of formulation and delivery device. *J Pharm Pharmacol.* 2012;64:1254–63.
35. Son Y-J, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the enhanced excipient growth application: effect of DPI design. *Respiratory Drug Delivery.* 2012;3:903–6.
36. Son Y-J, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the enhanced excipient growth application: effect of spray drying conditions. *Respir Drug Deliv.* 2012;3:899–902.
37. Son Y-J, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. *Int J Pharm.* 2013. doi:10.1016/j.ijpharm.2013.01.003.
38. Raula J, Lahde A, Kauppinen EI. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders. *Int J Pharm.* 2009;365:18–25.
39. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-Implications for *in vitro* testing. *J Aerosol Med.* 1993;6:99–110.
40. Ghalichi F, Deng X, Champlain AD, Douville Y, King M, Guidoin R. Low Reynolds number turbulence modeling of blood flow in arterial stenoses. *Biorheology.* 1998;35:281–94.
41. Wilcox DC. Turbulence modeling for CFD. 2nd ed. California: DCW Industries, Inc.; 1998.
42. Longest PW, Xi J. Condensational growth may contribute to the enhanced deposition of cigarette smoke particles in the upper respiratory tract. *Aerosol Sci Technol.* 2008;42:579–602.

43. Longest PW, Hindle M. Evaluation of the Respimat Soft Mist inhaler using a concurrent CFD and *in vitro* approach. *J Aerosol Med.* 2009;22:99–112.
44. Xi J, Longest PW, Martonen TB. Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways. *J Appl Physiol.* 2008;104:1761–77.
45. Longest PW, Vinchurkar S. Validating CFD predictions of respiratory aerosol deposition: effects of upstream transition and turbulence. *J Biomech.* 2007;40:305–16.
46. Longest PW, Hindle M, Das Choudhuri S, Xi J. Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth-throat geometry. *J Aerosol Sci.* 2008;39:572–91.
47. Allen MD, Raabe OG. Slip correction measurements of spherical solid aerosol particles in an improved Millikan apparatus. *Aerosol Sci Technol.* 1985;4:269–86.
48. Longest PW, Kleinstreuer C, Buchanan JR. Efficient computation of micro-particle dynamics including wall effects. *Comput Fluids.* 2004;33:577–601.
49. Morsi SA, Alexander AJ. An investigation of particle trajectories in two-phase flow systems. *J Fluid Mech.* 1972;55:193–208.
50. Longest PW, Xi J. Effectiveness of direct Lagrangian tracking models for simulating nanoparticle deposition in the upper airways. *Aerosol Sci Technol.* 2007;41:380–97.
51. Gosman AD, Ioannides E. Aspects of computer simulation of liquid-fueled combustors. *J Energy.* 1981;7:482–90.
52. Crowe CT, Troutt TR, Chung JN. Numerical models for two-phase turbulent flows. *Annu Rev Fluid Mech.* 1996;28:11–43.
53. Matida EA, Nishino K, Torii K. Statistical simulation of particle deposition on the wall from turbulent dispersed pipe flow. *Int J Heat Fluid Flow.* 2000;21:389–402.
54. Longest PW, Hindle M, Das Choudhuri S, Byron PR. Numerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental data. *Aerosol Sci Technol.* 2007;41:952–73.
55. Matida EA, Finlay WH, Grgic LB. Improved numerical simulation of aerosol deposition in an idealized mouth-throat. *J Aerosol Sci.* 2004;35:1–19.
56. Vinchurkar S, Longest PW. Evaluation of hexahedral, prismatic and hybrid mesh styles for simulating respiratory aerosol dynamics. *Comput Fluids.* 2008;37:317–31.
57. Longest PW, Vinchurkar S. Effects of mesh style and grid convergence on particle deposition in bifurcating airway models with comparisons to experimental data. *Med Eng Phys.* 2007;29:350–66.
58. Newman S. Respiratory drug delivery: Essential theory and practice. Richmond: RDD Online; 2009.
59. Finlay WH. The mechanics of inhaled pharmaceutical aerosols. San Diego: Academic; 2001.
60. Shur J, Lee SL, Adams W, Lionberger R, Tibbatts J, Price R. Effect of device design on the *in vitro* performance and comparability for capsule-based dry powder inhalers. *AAPS J.* 2012;14:667–76.